ArticleEMBO molecular medicine2019

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Eliana Mc Tacconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.